![Sample our Physical Sciences journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/110819/TOC-Subject-Sample-2021-Physical-Sciences.jpg"})
Abstract
A new series of rhodanines with phenyl substitution at the fifth position of rhodanine ring were designed targeting the PPAR-γ receptor for their possible antihyperglycemic activity. The rational design and molecular modeling studies were performed against PPAR-γ (PDB ID: 2PRG). The compounds were docked and thereafter subjected for the synthesis via dithiocarbamate formation followed by Knoevenagel condensation. Structures were confirmed by IR, NMR and Mass spectral analysis. All synthesized compounds were screened for in vitro glucose uptake assay using isolated hepatocytes. The Compounds A5 and B5 having N-(p-methoxy benzyl) at third position of rhodanine ring showed good glucose uptake activity. These two compounds were further studied for the in vivo antihyperglycemic study against dexamethasone induced insulin resistance. The compounds were tested at single dose level of 10 mg/kg, per oral. The compound B5 showed significant antihyperglycemic activity when compared with the standard drug, pioglitazone. The illustration, about the molecular design, synthesis, analysis, glucose uptake study and in vivo antihyperglycemic activity is reported here along with the structure activity relationships.
A series of N-Substituted rhodanines were synthesized by taking varied amines and aldehydes, via Knoevenagel condensation. The synthesized compounds were subjected to in vitro and in vivo glucose uptake assay. The compound showed comparable biological activity with reference to standard drug. Additionally, molecular docking and MD simulation study was performed to support the hypothesis.
Graphical Abstract
Acknowledgements
The authors are thankful to the management of JSS College of Pharmacy, Mysuru, Karnataka for providing the facilities to carry out this research.
Disclosure statement
All authors declare no conflict of interest.